Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung
Junichi Soh, Shinichi Toyooka, Shuji Ichihara et al. · Journal of Thoracic Oncology · 2008
Cited by 80 works. doi:10.1097/jto.0b013e318168d20a Open-access PDF
Authors
- Junichi Soh
- Shinichi Toyooka
- Shuji Ichihara
- Hiroaki Asano
- Naruyuki Kobayashi
- Hiroshi Suehisa
- Hiromasa Yamamoto
- Kouichi Ichimura
- Katsuyuki Kiura
- Adi F. Gazdar
- Hiroshi Date
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
- Histological Typing of Lung and Pleural Tumours
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer